|
US6090382A
(en)
|
1996-02-09 |
2000-07-18 |
Basf Aktiengesellschaft |
Human antibodies that bind human TNFα
|
|
DE19746868A1
(de)
*
|
1997-10-23 |
1999-04-29 |
Knoll Ag |
Verwendung von TNF-Antagonisten als Arzneimittel zur Behandlung von septischen Erkrankungen
|
|
US6844315B2
(en)
|
1998-05-20 |
2005-01-18 |
Erasmus Universiteit Rotterdam |
Immunoregulator
|
|
US20040202645A1
(en)
*
|
2003-04-08 |
2004-10-14 |
Khan Nisar Ahmed |
Administration of gene-regulatory peptides
|
|
US8680059B2
(en)
*
|
1998-05-20 |
2014-03-25 |
Biotempt B.V. |
Oligopeptide acetate and formulations thereof
|
|
US20030220258A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of ischemic events
|
|
US20050227925A1
(en)
*
|
2004-04-08 |
2005-10-13 |
Robbert Benner |
Compositions capable of reducing elevated blood urea concentration
|
|
US6921751B1
(en)
*
|
1998-05-20 |
2005-07-26 |
Erasmus Universiteit Rotterdam |
Immunoregulator
|
|
US7358330B2
(en)
|
2001-03-29 |
2008-04-15 |
Biotempt B.V. |
Immunoregulatory compositions
|
|
EP1300418A1
(en)
*
|
2001-10-04 |
2003-04-09 |
Erasmus Universiteit Rotterdam |
Gene regulation by oligopeptides
|
|
BR0111158A
(pt)
|
2000-05-12 |
2004-04-06 |
Genzyme Corp |
Composto e sais fisiológicos do mesmo, método para tratar uma condição mediana por tnf-a em um paciente
|
|
RU2181297C2
(ru)
|
2000-06-20 |
2002-04-20 |
Эпштейн Олег Ильич |
Способ лечения патологического синдрома и лекарственное средство
|
|
WO2002096461A1
(en)
*
|
2001-05-25 |
2002-12-05 |
Abbott Gmbh & Co. Kg |
Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients
|
|
CA2385745C
(en)
|
2001-06-08 |
2015-02-17 |
Abbott Laboratories (Bermuda) Ltd. |
Methods of administering anti-tnf.alpha. antibodies
|
|
US7925894B2
(en)
*
|
2001-07-25 |
2011-04-12 |
Seagate Technology Llc |
System and method for delivering versatile security, digital rights management, and privacy services
|
|
US20030220261A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Khan Nisar Ahmed |
Treatment of iatrogenic disease
|
|
US20030220260A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Khan Nisar Ahmed |
Peptide compositions
|
|
US20080242837A1
(en)
*
|
2001-12-21 |
2008-10-02 |
Khan Nisar A |
Peptide compositions
|
|
US7560433B2
(en)
|
2001-12-21 |
2009-07-14 |
Biotempt B.V. |
Treatment of multiple sclerosis (MS)
|
|
US20030224995A1
(en)
*
|
2001-12-21 |
2003-12-04 |
Khan Nisar Ahmed |
Treatment of burns
|
|
US20030220257A1
(en)
*
|
2001-12-21 |
2003-11-27 |
Robbert Benner |
Treatment of trauma
|
|
US7786084B2
(en)
*
|
2001-12-21 |
2010-08-31 |
Biotempt B.V. |
Treatment of burns
|
|
US7501391B2
(en)
*
|
2001-12-21 |
2009-03-10 |
Biotempt B.V. |
Treatment of transplant survival
|
|
US20080318871A1
(en)
*
|
2001-12-21 |
2008-12-25 |
Khan Nisar A |
Treatment of neurological disorders
|
|
US20040013661A1
(en)
*
|
2001-12-21 |
2004-01-22 |
Gert Wensvoort |
Stratification
|
|
US20030161828A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Abbott Gmbh & Co. Kg |
Use of TNF antagonists as drugs for the treatment of patients with an inflammatory reaction and without suffering from total organ failure
|
|
US7860806B2
(en)
*
|
2002-03-12 |
2010-12-28 |
Nokia Corporation |
System and method for charging for data reception
|
|
US20040018197A1
(en)
*
|
2002-04-26 |
2004-01-29 |
Promega Corporation |
Treatment for weight loss
|
|
US20040009172A1
(en)
*
|
2002-04-26 |
2004-01-15 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
US20030206898A1
(en)
|
2002-04-26 |
2003-11-06 |
Steven Fischkoff |
Use of anti-TNFalpha antibodies and another drug
|
|
BR0312785A
(pt)
*
|
2002-07-19 |
2005-08-30 |
Abbott Biotech Ltd |
Tratamento de desordens relacionadas a tnf(alfa)
|
|
UA76639C2
(uk)
|
2002-08-02 |
2006-08-15 |
Олєг Ільіч Епштєйн |
Гомеопатичний лікарський засіб та спосіб лікування еректильних дисфункцій
|
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
|
MY150740A
(en)
|
2002-10-24 |
2014-02-28 |
Abbvie Biotechnology Ltd |
Low dose methods for treating disorders in which tnf? activity is detrimental
|
|
ES2363914T3
(es)
*
|
2002-11-21 |
2011-08-19 |
Genzyme Corporation |
Utilización de un derivado de diamida para inhibir el rechazo crónico de un transplante.
|
|
AU2003291143A1
(en)
*
|
2002-11-21 |
2004-06-18 |
Genzyme Corporation |
Combination of diamide derivatives and immunosuppressive agents for induction of immune tolerance
|
|
EP1578799B8
(en)
*
|
2002-12-02 |
2011-03-23 |
Amgen Fremont Inc. |
Antibodies directed to tumor necrosis factor and uses thereof
|
|
US7101978B2
(en)
*
|
2003-01-08 |
2006-09-05 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
US20090227505A1
(en)
*
|
2004-01-07 |
2009-09-10 |
Biotempt B.V. |
Methods and uses for protein breakdown products
|
|
US7435799B2
(en)
*
|
2004-01-08 |
2008-10-14 |
Applied Molecular Evolution |
TNF-α binding molecules
|
|
TWI556829B
(zh)
|
2004-04-09 |
2016-11-11 |
艾伯維生物技術有限責任公司 |
用於治療ＴＮＦα相關失調症之多重可變劑量療法
|
|
EP1807111A4
(en)
*
|
2004-10-08 |
2009-05-27 |
Abbott Biotech Ltd |
SYNCYTIAL RESPIRATORY VIRUS INFECTION (RSV)
|
|
MX2007014440A
(es)
|
2005-05-16 |
2008-02-11 |
Abbott Biotech Ltd |
Uso de inhibidor de tnf para tratamiento de poliartritis erosiva.
|
|
EP1904086A2
(en)
*
|
2005-07-05 |
2008-04-02 |
Biotempt B.V. |
Treatment of tumors
|
|
US20070041905A1
(en)
*
|
2005-08-19 |
2007-02-22 |
Hoffman Rebecca S |
Method of treating depression using a TNF-alpha antibody
|
|
EP1864692A1
(en)
*
|
2006-06-07 |
2007-12-12 |
Biotempt B.V. |
Use of peptides for the control of radiation injury
|
|
RU2309732C1
(ru)
|
2006-03-13 |
2007-11-10 |
Олег Ильич Эпштейн |
Спрессованная твердая оральная форма лекарственного препарата и способ получения твердой оральной формы лекарственного препарата
|
|
SG170837A1
(en)
|
2006-04-05 |
2011-05-30 |
Abbott Biotech Ltd |
Antibody purification
|
|
EP2010214A4
(en)
*
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
USES AND COMPOSITIONS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
|
|
US20080118496A1
(en)
*
|
2006-04-10 |
2008-05-22 |
Medich John R |
Uses and compositions for treatment of juvenile rheumatoid arthritis
|
|
US9605064B2
(en)
|
2006-04-10 |
2017-03-28 |
Abbvie Biotechnology Ltd |
Methods and compositions for treatment of skin disorders
|
|
EP2007426A4
(en)
|
2006-04-10 |
2010-06-16 |
Abbott Biotech Ltd |
COMPOSITIONS FOR THE TREATMENT OF PSORIASTIC POLYARTHRITIS AND THEIR APPLICATIONS
|
|
US20090317399A1
(en)
*
|
2006-04-10 |
2009-12-24 |
Pollack Paul F |
Uses and compositions for treatment of CROHN'S disease
|
|
US20080131374A1
(en)
*
|
2006-04-19 |
2008-06-05 |
Medich John R |
Uses and compositions for treatment of rheumatoid arthritis
|
|
PT2120991E
(pt)
*
|
2007-02-12 |
2014-05-02 |
Biotempt Bv |
Tratamento d a hemorragia traumática com oligopéptidos curtos
|
|
US8062864B2
(en)
*
|
2007-05-21 |
2011-11-22 |
Alderbio Holdings Llc |
Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
|
|
US20090238825A1
(en)
*
|
2007-05-21 |
2009-09-24 |
Kovacevich Brian R |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
US8252286B2
(en)
|
2007-05-21 |
2012-08-28 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US9701747B2
(en)
|
2007-05-21 |
2017-07-11 |
Alderbio Holdings Llc |
Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
|
|
US7906117B2
(en)
|
2007-05-21 |
2011-03-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
CA2688146C
(en)
|
2007-05-21 |
2018-03-06 |
Alder Biopharmaceuticals, Inc. |
Antibodies to il-6 and use thereof
|
|
US8178101B2
(en)
|
2007-05-21 |
2012-05-15 |
Alderbio Holdings Inc. |
Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
|
|
US8404235B2
(en)
|
2007-05-21 |
2013-03-26 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
WO2008144757A1
(en)
*
|
2007-05-21 |
2008-11-27 |
Alder Biopharmaceuticals, Inc. |
Novel rabbit antibody humanization methods and humanized rabbit antibodies
|
|
EP2171451A4
(en)
|
2007-06-11 |
2011-12-07 |
Abbott Biotech Ltd |
METHOD FOR TREATING JUVENILIAN IDIOPATHIC ARTHRITIS
|
|
US8323649B2
(en)
*
|
2008-11-25 |
2012-12-04 |
Alderbio Holdings Llc |
Antibodies to IL-6 and use thereof
|
|
US8992920B2
(en)
|
2008-11-25 |
2015-03-31 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of arthritis
|
|
US8420089B2
(en)
|
2008-11-25 |
2013-04-16 |
Alderbio Holdings Llc |
Antagonists of IL-6 to raise albumin and/or lower CRP
|
|
US8337847B2
(en)
|
2008-11-25 |
2012-12-25 |
Alderbio Holdings Llc |
Methods of treating anemia using anti-IL-6 antibodies
|
|
US9452227B2
(en)
|
2008-11-25 |
2016-09-27 |
Alderbio Holdings Llc |
Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
|
|
US9212223B2
(en)
|
2008-11-25 |
2015-12-15 |
Alderbio Holdings Llc |
Antagonists of IL-6 to prevent or treat thrombosis
|
|
US9775921B2
(en)
|
2009-11-24 |
2017-10-03 |
Alderbio Holdings Llc |
Subcutaneously administrable composition containing anti-IL-6 antibody
|
|
WO2011066374A2
(en)
|
2009-11-24 |
2011-06-03 |
Alder Biopharmaceuticals, Inc. |
Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
|
|
MX2013000543A
(es)
|
2010-07-15 |
2013-10-28 |
Oleg Iliich Epshtein |
Un metodo para aumentar el efecto de una forma activa potenciada de un anticuerpo.
|
|
US8637030B2
(en)
|
2010-07-15 |
2014-01-28 |
Oleg I. Epshtein |
Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
|
|
US9304134B2
(en)
|
2010-11-23 |
2016-04-05 |
Alderbio Holdings Llc |
Anti-IL-6 antibodies for the treatment of anemia
|
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
|
US9150645B2
(en)
|
2012-04-20 |
2015-10-06 |
Abbvie, Inc. |
Cell culture methods to reduce acidic species
|
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
|
EP2948178A4
(en)
|
2013-01-25 |
2016-07-20 |
Thymon Llc |
COMPOSITIONS FOR SELECTIVELY REDUCING CIRCULATING BIOACTIVE SOLUBLE TNF AND METHOD FOR TREATING TNF-MEDIATED ILLNESS
|
|
EP2830651A4
(en)
|
2013-03-12 |
2015-09-02 |
Abbvie Inc |
HUMAN ANTIBODIES THAT BIND TNF-ALPHA AND PREPARATION METHODS
|
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
|
WO2016160976A2
(en)
|
2015-03-30 |
2016-10-06 |
Abbvie Inc. |
Monovalent tnf binding proteins
|
|
EP3078675A1
(en)
|
2015-04-10 |
2016-10-12 |
Ares Trading S.A. |
Induction dosing regimen for the treatment of tnf alpha mediated disorders
|
|
JOP20190162A1
(ar)
|
2016-12-30 |
2019-06-27 |
Biocad Joint Stock Co |
تركيبة صيدلانية مائية من جسم مضاد لـ tnf? أحادي النسيلة معاود الارتباط الجيني
|